Black Hairy Tongue Associated with Erlotinib Treatment in a Patient with Advanced Lung Cancer

Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). There have been many reports of the mucocutaneous side effects related to several EGFR inhibitors (EGFRIs). However, no case of black hairy tongue (BHT) associated with EGFRI has been reported. Herein,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Jin Seob, Lee, Ji Yeoun, Kim, Mi Kyeong, Yoon, Tae Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Dermatological Association; The Korean Society for Investigative Dermatology 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229953/
https://www.ncbi.nlm.nih.gov/pubmed/22148027
http://dx.doi.org/10.5021/ad.2011.23.4.526
Descripción
Sumario:Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). There have been many reports of the mucocutaneous side effects related to several EGFR inhibitors (EGFRIs). However, no case of black hairy tongue (BHT) associated with EGFRI has been reported. Herein, we report the first case of erlotinib-induced BHT in a 61-year-old man with advanced lung cancer. Considering recent use of EGFRIs worldwide, dermatologists should recognize the possible occurrence of BHT associated with EGFRIs such as erlotinib.

Ejemplares similares